Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 9, 2011, Pages 1380-1388

  Jin, Young Joo ^a   Shim, Ju Hyun ^a   Lee, Han Chu ^a   Yoo, Dong Jun ^a   Kim, Kang Mo ^a   Lim, Young Suk ^a   Suh, Dong Jin ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Entecavir; Hepatitis B virus; Hepatocellular carcinoma; Overall survival; Recurrence free survival

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS E ANTIGEN; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 80052390410     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06776.x     Document Type: Article

References (39)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
2. Chan HL, Tse CH, Mo F etal. High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J. Clin. Oncol. 2008; 26: 177-82.
3. Hung IF, Poon RT, Lai CL, Fung J, Fan ST, Yuen MF. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am. J. Gastroenterol. 2008; 103: 1663-73.
4. Wu JC, Huang YH, Chau GY etal. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J. Hepatol. 2009; 51: 890-7.
5. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
6. Liaw YF, Sung JJ, Chow WC etal. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004; 351: 1521-31.
7. Kubo S, Tanaka H, Takemura S etal. Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus. Hepatol. Res. 2007; 37: 94-100.
8. Li N, Lai EC, Shi J etal. A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection. Ann. Surg. Oncol. 2010; 17: 179-85.
9. Yoshida H, Goto E, Sato T etal. Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma. Hepatol. Int. 2008; 2: 89-94.
10. Kim JH, Park JW, Koh DW, Lee WJ, Kim CM. Efficacy of lamivudine on hepatitis B viral status and liver function in patients with hepatitis B virus-related hepatocellular carcinoma. Liver Int. 2009; 29: 203-7.
11. Lai CL, Chien RN, Leung NW etal. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. 1998; 339: 61-8.
12. Lok AS, Lai CL, Leung N etal. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-22.
13. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
14. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J. Hepatol. 2009; 50: 227-42.
15. Chang TT, Lai CL, Kew Yoon S etal. Entecavir treatment for up to 5years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422-30.
16. Tenney DJ, Rose RE, Baldick CJ etal. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5years of therapy. Hepatology 2009; 49: 1503-14.
17. Schiff E, Simsek H, Lee WM etal. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am. J. Gastroenterol. 2008; 103: 2776-83.
18. Shim JH, Lee HC, Kim KM etal. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J. Hepatol. 2010; 52: 176-82.
19. Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl. Clin. Surg. 1964; 1: 1-85.
20. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 1973; 60: 646-9.
21. Shim JH, Suh DJ, Kim KM etal. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. Hepatology 2009; 50: 1064-71.
22. Yang JD, Kim WR, Coelho R etal. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 2010; 9: 64-70.
23. Di Lelio A, Cestari C, Lomazzi A, Beretta L. Cirrhosis: diagnosis with sonographic study of the liver surface. Radiology 1989; 172: 389-92.
24. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-50.
25. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin. Liver Dis. 2005; 25: 143-54.
26. Yokosuka O, Takaguchi K, Fujioka S etal. Long-term use of entecavir in nucleoside-naive Japanese patients with chronic hepatitis B infection. J. Hepatol. 2010; 52: 791-9.
27. Gish RG, Lok AS, Chang TT etal. Entecavir therapy for up to 96weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 1437-44.
28. Kuzuya T, Katano Y, Kumada T etal. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2007; 22: 1929-35.
29. Piao CY, Fujioka S, Iwasaki Y etal. Lamivudine treatment in patients with HBV-related hepatocellular carcinoma-using an untreated, matched control cohort. Acta Med. Okayama 2005; 59: 217-24.
30. Hann HW, Bergin D, Coben R, DiMarino AJ. Prevention of new hepatocellular carcinoma with concomitant antiviral therapy in chronic hepatitis B patients whose initial tumor was successfully ablated. Int. J. Cancer 2011; 128: 740-3.
31. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-86.
32. Chen CJ, Yang HI, Su J etal. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
33. Kim CM, Koike K, Saito I, Miyamura T, Jay GH. Bx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991; 351: 317-20.
34. Paterlini P, Poussin K, Kew M, Franco D, Brechot C. Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. Hepatology 1995; 21: 313-21.
35. Chen CJ, Yang HI, Iloeje UH. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 2009; 49: S72-84.
36. Lai CL, Gane E, Liaw YF etal. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 2007; 357: 2576-88.
37. Yuen MF, Fong DY, Wong DK, Yuen JC, Fung J, Lai CL. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 2007; 46: 1695-703.
38. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000; 89: 500-7.
39. Portolani N, Coniglio A, Ghidoni S etal. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann. Surg. 2006; 243: 229-35.